Drugs / Anastrazole
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04316169 | Oct 2021 → Jan 2027 | female breast carcinoma | Medical College of Wisconsin | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT00309855 | Dec 2005 → Aug 2008 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06075953 | Feb 2024 → Nov 2028 expected | ductal breast carcinoma in situ | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 2 | NCT03624244 | Jan 2019 → Jan 2028 expected | uterine corpus endometrial stromal sarcoma | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 2 | NCT00921115 | May 2009 → Apr 2015 | invasive breast carcinoma | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00259090 | Apr 2004 → Oct 2008 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03421639 | Dec 2017 → Sep 2024 | adenomyosis, dysmenorrhea, infertility disorder | Centre for Endocrinology and Reproductive Medicine, Italy | Unknown | No outcome recorded |
| Phase 4 | NCT01769781 | Jan 2013 → Jul 2015 | endometriosis | Centre for Endocrinology and Reproductive Medicine, Italy | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00983554 | Jun 2005 → May 2009 | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Unknown | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT04023292 Comparator | Jul 2019 → Jul 2023 | breast neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03321981 Background | Jan 2018 → Oct 2022 | breast carcinoma | Merus B.V. | Completed | No outcome recorded |
| Phase 2 | NCT00240071 Background | Oct 2005 → Mar 2009 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 3 | NCT00556374 Background | Dec 2006 → Oct 2014 | breast cancer | Amgen | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anastrazole | “aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)” NCT00240071 ↗12“An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting” NCT00556374 ↗ “ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE” NCT03624244 ↗ “tamoxifen, Letrozole, Anastrazole, Exemestane, etc.” NCT04023292 ↗ “1mg/day of Anastrazole for 3 months” NCT03421639 ↗ “anastrazole” NCT03321981 ↗ |
| Known as | Arimidex (anastrazole) | “Arimidex (anastrazole)” NCT00240071 ↗ |
| Action | Inhibit | “Greater estrogen-receptor (ER) blockade may feasibly be achieved by combining fulvestrant with anastrozole.” PMID 23497452 ↗ Mar 2013 |
| Route | Oral | “anastrazole 1mg/d PO” NCT00240071 ↗ |